A central point in the profile of Nilotinib is the relationship between its molecular action and the cancer setting in which it is used. Potent inhibitor of BCR-ABL, including several imatinib-resistant mutants. The target is a disease-defining tyrosine-kinase pathway in Philadelphia chromosome-positive leukemia, making molecular disease status central to its use. The record identifies it as BCR-ABL TKI within Targeted Therapy; BCR-ABL Tyrosine Kinase Inhibitor and lists CML among the associated tumor types. The principal indications are Philadelphia chromosome-positive CML. Regimen examples include Nilotinib monotherapy. The combination context matters: depending on the disease, the agent may be used alone or alongside other systemic treatments as specified in the database. Molecular and disease-specific eligibility can therefore be more important than tumor location alone when the treatment is considered. Any biomarker or disease-state requirement included in the indication should be considered when interpreting the entry. The same broad therapeutic class can contain medicines with different targets and therefore different clinical uses. This description intentionally remains descriptive rather than prescriptive, with no patient-specific dosing or treatment instructions. Current labels and applicable oncology guidelines should be consulted to confirm present-day indications and combinations.